PEPTIDE COMPARISON

BPC-157 vs TB-500

A source-backed comparison of two unapproved recovery-market peptides.

QUICK ANSWER

BPC-157 vs TB-500: the main difference.

Neither has established human efficacy for recovery. BPC-157 has a broader preclinical literature; TB-500 has the added problem that evidence about full-length thymosin beta-4 is often applied to a different or poorly defined product.

Decision field	BPC-157	TB-500
Human research	Very limited	Very limited and often conflated with thymosin beta-4
Primary research	GI, inflammation, tissue models	Actin biology and tissue-repair models
FDA status	Not approved	Not approved
Core evidence problem	Translation from animals to people	Entity identity plus translation
2026 WADA	Prohibited at all times	Prohibited at all times

SOURCES

BPC-157 vs TB-500 sources.

FDA / 2026Bulk substances that may present significant safety risksU.S. FDA Review / 2026BPC-157 as an investigational peptide therapeuticPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Review / 2015Thymosin beta-4 and tissue repairPubMed

BPC-157 vs TB-500: the main difference.

BPC-157 vs TB-500 sources.

Questions related to BPC-157 vs TB-500.

Compare the next decision.